

Resource Summary Report

Generated by [RRID](#) on Aug 19, 2026

[pCI-neo-cOVA](#)

RRID:Addgene_25097

Type: Plasmid

Proper Citation

RRID:Addgene_25097

Plasmid Information

URL: <http://www.addgene.org/25097>

Proper Citation: RRID:Addgene_25097

Insert Name: cytoplasmic ovalbumin

Organism: Gallus gallus

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:20133734](#)

Vector Backbone Description: Backbone Size:5472; Vector Backbone:pCI-neo; Vector Types:Mammalian Expression, Bacterial Expression; Bacterial Resistance:Ampicillin

Plasmid Name: pCI-neo-cOVA

Record Creation Time: 20220422T222111+0000

Record Last Update: 20260815T081237+0000

Ratings and Alerts

No rating or validation information has been found for pCI-neo-cOVA.

No alerts have been found for pCI-neo-cOVA.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chua J, et al. (2026) A tumor-intrinsic WNT-inhibitory NOTUM program drives immune resistance in microsatellite stable colorectal cancer. *Cell reports. Medicine*, 7(5), 102776.

Sodhi SS, et al. (2026) Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy. *Journal for immunotherapy of cancer*, 14(5).

Manrique-Rincón AJ, et al. (2025) Simulating CD8 T cell exhaustion: A comprehensive approach. *iScience*, 28(7), 112897.

Flem-Karlsen K, et al. (2025) Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity. *Cancer research*, 85(21), 4139.

Mowat C, et al. (2025) NLRP3 activation promotes cGAS/STING signaling and antitumor immunity by colorectal cancer cells. *Cancer immunology, immunotherapy : CII*, 74(8), 238.

Jiménez-Lasheras B, et al. (2025) NEDDylation Regulates CD8+ T-cell Metabolism and Antitumor Immunity. *Cancer immunology research*, 13(7), 1004.

Chen S, et al. (2025) CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. *Nature communications*, 16(1), 4069.

Ren W, et al. (2024) Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. *Nature communications*, 15(1), 9.

Lacotte S, et al. (2023) Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth. *Oncoimmunology*, 12(1), 2184991.

Garcia-Fabiani MB, et al. (2023) H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas. *bioRxiv : the preprint server for biology*.

Shen M, et al. (2022) Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. *Nature cancer*, 3(1), 60.

Goral A, et al. (2022) A Specific CD44^{lo} CD25^{lo} Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia. *Frontiers in immunology*, 13, 781364.

Reticker-Flynn NE, et al. (2022) Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. *Cell*, 185(11), 1924.

Mowat C, et al. (2021) Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. *The Journal of experimental medicine*, 218(9).

Wang X, et al. (2021) In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. *Cell*, 184(21), 5357.

Yamamoto K, et al. (2020) Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. *Nature*, 581(7806), 100.

Jiang Y, et al. (2020) Engineered Cell-Membrane-Coated Nanoparticles Directly Present Tumor Antigens to Promote Anticancer Immunity. *Advanced materials (Deerfield Beach, Fla.)*, 32(30), e2001808.

Alghamri MS, et al. (2020) Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. *Methods in enzymology*, 631, 91.

Tsukamoto H, et al. (2019) Impaired antigen-specific lymphocyte priming in mice after Toll-like receptor 4 activation via induction of monocytic myeloid-derived suppressor cells. *European journal of immunology*, 49(4), 546.

Barilla RM, et al. (2019) Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma. *Nature communications*, 10(1), 1424.